IBRX ImmunityBio, Inc.

$7.57

ImmunityBio, Inc. (IBRX) is expected to report earnings on November 3, 2026, before the market open. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +12.0% since its last earnings release on August 4, 2026.

ImmunityBio Beat Consensus Estimates
Tuesday, August 4, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · 7:30 AM ET
Earnings Whisper
-
vs ($0.08)
Rev est $60.75M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.36

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ImmunityBio, Inc.

ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.

Sector

Healthcare

Industry

Biotechnology